INE-1001 is being developed for post-surgical ocular pain and is currently under preclinical development progressing towards a first-in-human Phase 1 study to be initiated by 2025 in Spain
Preclinical evidence
In animal models, INE-1001 was well tolerated upon repeated instillation and produced a rapid-onset, dose-dependent selective effect reducing corneal mechanical sensitivity